Articles tagged with Ovarian Cancer
Researchers found that only 6.8% of cancer patients underwent genetic testing within two years of diagnosis, with lower rates among Black, Hispanic, and Asian patients. The low rates are attributed to lack of integration of test results into cancer management and prevention.
A phase I study found significant clinical benefit of the ADC luveltamab tazevibulin in patients with recurrent ovarian cancer expressing high levels of folate receptor alpha, with an overall response rate of 37.5% and a 44% response rate at higher doses.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
The PARIS Test, a CLIA-certified drug sensitivity assay, uses patient-derived tumor organoids to screen an array of drugs and develop personalized treatment reports. Ibrutinib, a BTK inhibitor approved only for certain leukemias and lymphomas, was identified as the optimal treatment for a patient with ovarian cancer.
Researchers have identified three subtypes of ovarian high-grade serous carcinoma (HGSC) based on genomic changes, which may help tailor therapies. The study's findings could improve treatment outcomes for patients with this aggressive subtype.
Overweight and obesity in early adulthood are associated with increased risks of colorectal cancer and non-colorectal gastrointestinal cancers. The study highlights the need for further exploration into the mechanisms driving these associations.
A new study finds that one-time genomic screening of adults aged 20-60 for hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia is cost-effective based on quality-adjusted life-year measures. The study suggests that this approach could improve disease management and reduce healthcare costs.
A recent Fred Hutchinson Cancer Center study found that fibroids were associated with an increased risk of ovarian cancer in both Black and white women, while hysterectomy modified this risk for white women but not Black women. The study highlights the need for further research into racial disparities in ovarian cancer risk.
A new study suggests combining digital cancer risk assessment with point-of-care genetic testing can help overcome clinical workflow challenges that prevent at-risk patients from accessing genetic testing. The approach more than doubled the average uptake of genetic testing, showing promise for cancer prevention and detection.
Researchers found that removing ovaries during a benign hysterectomy increases the risk of hospitalization for cardiovascular disease in premenopausal women, but not necessarily for cancer. The study supports current recommendations to conserve ovaries in premenopausal patients at low risk for ovarian cancer.
Researchers have reported promising results in rare gynecologic cancers from the DART immunotherapy trial, with durable responses and complete remissions observed in patients. The findings suggest a potential new treatment approach for these previously underserved patient populations.
A new target for drug-resistant ovarian cancer has been identified through a preclinical study led by researchers at Penn Medicine. An antibody-drug conjugate targeting B7-H4 showed significant anti-tumor activity and sustained response in treatment-resistant models.
A new study reveals the mechanism of BRCA2's DNA repair function, understanding its role in breast and ovarian cancer development. The findings also provide insights into developing targeted cancer therapies by inhibiting DNA repair mechanisms.
A phase II trial investigating the combination of ribociclib and letrozole showed a response rate of 23%, progression-free survival of 19.1 months, and duration of response of 19.1 months in patients with recurrent low-grade serous ovarian cancer.
Researchers at the Mayo Clinic found that surgical removal of both ovaries in women under 43 increases their risk of developing Parkinson's disease and parkinsonism. The study used health record data from the Rochester Epidemiology Project to analyze over 2,750 women who underwent bilateral oophorectomy.
Researchers from Swansea University and Université Grenoble Alpes demonstrate the effectiveness of selenium nanoparticles in killing ovarian cancer cell models. The study reveals a novel biological mechanism underlying the anti-cancer effect, involving histone methylatransferases and epigenetic processes.
Researchers discovered that quiescent ovarian cancer cells secrete follistatin, which induces resistance in neighboring cells and worsens survival rates. Targeting this protein may improve chemotherapy response and boost survival in patients with aggressive ovarian cancer.
A new study found that women with BRCA1 or BRCA2 mutations have a cumulative risk of 49% developing any type of cancer after age 50. Risk-reducing surgeries like mastectomies and BSOs can lower this risk, but many women opt out despite elevated risk. Genetic testing is crucial for accurate risk assessment and personalized care.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
A new study suggests that higher consumption of ultra-processed foods may be linked to an increased risk of developing and dying from cancer. The study found that each 10% increase in ultra-processed food consumption was associated with a 2% increase in cancer incidence, as well as a 6% increase in mortality from cancer.
A study found a link between pain and indigestion medication purchases and ovarian cancer diagnoses, suggesting earlier symptom recognition. The research suggests that loyalty card data can be used to identify potential ovarian cancer cases.
A study suggests that loyalty card data on over-the-counter medicine purchases could help spot ovarian cancer cases earlier. Women with ovarian cancer were found to buy more pain and indigestion medications before diagnosis, often up to 8 months prior. This could lead to improved survival rates if symptoms are picked up earlier.
A new study suggests that acupressure before surgery can reduce anxiety, while acupuncture during surgery may provide additional relief from severe pain. The research found that patients who received these treatments had better recovery scores and lower levels of pain and anxiety compared to those who received standard care.
A study by Mayo Clinic researchers found a specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer. The discovery strengthens evidence that the bacterial component of the microbiome is an important indicator for early detection, diagnosis, and prognosis of ovarian cancer.
A new genetic test has been developed to identify ovarian cancer patients who benefit from PARP inhibitors, a treatment option with significant improvements in prognosis. The test has been optimized for the Finnish population and is clinically approved, allowing for targeted treatment and reduced adverse effects.
A new software developed by researchers at Cold Spring Harbor Laboratory can accurately infers continental ancestry from tumor DNA and RNA. This technology has the potential to lead to more targeted and personalized cancer treatments by identifying genetic connections between cancer and race or ethnicity.
Researchers at Memorial Sloan Kettering Cancer Center have discovered several mechanisms of immune escape that contribute to ovarian cancer's resistance to immunotherapy. The study reveals that ovarian tumors develop new mutations to evade the immune system as they spread, making it challenging to identify a marker for predicting respo...
The National Cancer Institute awards $10.5 million to USC's Division of Biostatistics to develop statistical methods for uncovering new risk factors associated with cancer by integrating large volumes of health, genomic, and exposure data. The project aims to provide new insights into complex biological processes and discoveries of nov...
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
In a recent study, researchers targeted the POL theta enzyme to inhibit DNA production in cancer cells. The approach represents a new method for developing specific therapies for patients with BRCA1 mutations.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A study of 11,945 people found that those with type 2 diabetes are more likely to be diagnosed with advanced cancer if the condition is not screened for routinely. Researchers identified a 26% increased risk of metastasis in patients with pre-existing type 2 diabetes.
A new study found that BRCA1/2 mutation-associated cancers have specific features that contribute to their high risk of recurrence, including changes in the BRCA2 protein's messenger-RNA molecule. The researchers identified multiple novel markers of therapeutic resistance, highlighting the importance of tumor profiling at treatment time.
A new study published in JNCCN found significant disparities in ovarian cancer treatment based on patient race, ability to pay, and healthcare access. Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment compared to White patients.
Research suggests that antibiotics used in ovarian cancer treatment can accelerate cancer progression and lower survival rates. Reintroducing healthy gut bacteria may slow down cancer growth and restore sensitivity to chemotherapy.
A specialized triage algorithm, ROCA test, enables earlier stage diagnosis in women deferring preventive surgery, saving NHS costs. The approach results in fewer major surgical interventions and lower risk of wider disease spread.
Two new discoveries led by Cedars-Sinai Cancer investigators improve understanding of ovarian cancer's development and suggest personalized therapeutic approaches. They identified four new genetic regions linked to increased ovarian cancer risk and found that some tumors may develop resistance to chemotherapy from an early stage.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
A meta-analysis of 410 articles from 68 countries found that patients in lower-income countries take up to four times longer to initiate care for cancer treatment. Cancers causing non-specific symptoms, such as myeloma and colorectal cancer, typically take the longest to diagnose.
A new potential antitumor drug, TRIP, causes rapid protein aggregation, hyperactivating the unfolded protein response and leading to programmed cell death in ovarian cancer cells. The Fe-S cluster biogenesis factor NUBP2 is identified as the probable starting point for the cellular processes triggered by TRIP.
A global study found that early-stage mucinous ovarian cancer patients with an infiltrative pattern of invasion have poorer survival chances. This discovery could lead to more targeted treatment strategies for these patients. Researchers hope to develop targeted drugs and align treatment guidelines worldwide.
MUSC researcher Joe Delaney, Ph.D., is awarded $453,000 to investigate aneuploidy in ovarian cancer. His project aims to target the cadmium response pathway and develop a new type of cancer drug for patients.
Researchers developed a computational platform to identify metabolic vulnerabilities in ovarian cancer genes, suggesting opportunities for targeted therapies. The study found that certain genetic alterations can create vulnerabilities in cancer cell metabolism, which can be exploited to selectively kill cancer cells.
Researchers at Oregon State University have developed a promising messenger RNA therapy for ovarian cancer, which also shows promise in treating cachexia, a muscle-wasting condition associated with cancer. The treatment uses lipid nanoparticles to deliver mRNA that triggers the production of the follistatin protein within cancer clusters.
Researchers at Cleveland Clinic link HSD3B1 genotype to higher risk of type 2 endometrial cancer, which is more aggressive and has lower survival rates than type 1. The study builds on previous associations with breast and prostate cancer, suggesting the gene could serve as a biomarker for certain subtypes.
A new study has successfully predicted ovarian cancer in patients with a pelvic mass using a simple blood test. The liquid biopsy technology captures circulating tumor cells, allowing for genetic analysis in just a couple of hours, which can help diagnose the disease earlier.
Rice University researchers have developed a treatment combining drug factory implants producing interleukin-2 with checkpoint inhibitors to eradicate advanced-stage mesothelioma tumors in mice. The treatment resulted in complete tumor destruction in all seven treated mice, offering a promising approach to this aggressive lung cancer.
A new study published in the Journal of Clinical Oncology found that frequent aspirin use is linked with a 13% reduced risk of ovarian cancer in individuals with multiple risk factors. Aspirin benefitted most subgroups, including those with endometriosis and obesity.
Researchers discover G6PD's pivotal role in activating pentose phosphate pathway to counter oxidative stress, leading to increased cell death and tumor shrinkage. Ovarian cancer cells' reliance on fatty acid metabolism fuels oxidative compound production, which can be offset by G6PD inhibition.
A phase III clinical trial found that taxane maintenance therapy did not significantly improve overall survival for women with advanced ovarian, peritoneal, and tubal cancers. The treatment resulted in significant gastrointestinal and neurological adverse events.
Wistar scientists have identified a novel therapeutic approach that inhibits the gene KDM5A, which improves immune cell infiltration and attack on tumors. This approach has shown promising results in both in vitro and in vivo studies, including reduced tumor burden and improved survival rates in mice with ovarian cancer.
Researchers from Bern and Geneva universities will receive $878,000 in funding to investigate mechanisms of resistance to PARPi inhibitors in BRCA-mutated ovarian cancer. The goal is to develop new targeted therapies to improve survival rates for patients with drug-resistant ovarian cancer.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
New research suggests vitamin D can effectively prevent ovarian cancer by restoring the body's natural defenses. The study found that vitamin D counteracts the process of peritoneal metastasis, which allows cancer cells to spread, and strengthens the barrier effect of mesothelial cells.
A new nanosensor platform uses machine learning to analyze spectral signatures of carbon nanotubes for early detection of ovarian cancer. The approach detects biomarkers and recognizes the cancer itself, offering a promising alternative to traditional methods.
Researchers identified OR2H1 as an effective target for CAR T cells in solid tumors, inhibiting growth in lung and ovarian cancer. The study suggests that targeting this protein could lead to the development of new CAR T therapies for a wide variety of patients with solid tumors.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.